Mutations Clinical Trials in New York, New York
11 recruitingNew York, New York
Showing 1–11 of 11 trials
Recruiting
Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Duke Street Bio Ltd180 enrolled18 locationsNCT06458712
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 1Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals36 enrolled16 locationsNCT05788536
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd67 enrolled14 locationsNCT05886920
Recruiting
Phase 1
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Pancreas Registry and High Risk Registry
Pancreas CancerPancreatitisChronic Pancreatitis+3 more
Icahn School of Medicine at Mount Sinai1,368 enrolled2 locationsNCT02775461
Recruiting
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Phase 1
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.150 enrolled23 locationsNCT06366789
Recruiting
CNGB1 and Allied Disorders
Retinitis Pigmentosa Associated With CNGB1 Mutations
Columbia University20 enrolled6 locationsNCT04639635
Recruiting
Phase 2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502